CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 66 enrolled
Drug / intervention
Contrast Ultrasounddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02022436
NCT02022436Phase 2Completed
CompareCT.gov

Aortic Wall Behavior as a Predictor of Aortic Aneurysm Growth and Rupture

Rabih A. Chaer·interventional·Posted Dec 27, 2013·Updated Nov 13, 2023

In Brief

A Phase 2 clinical trial evaluating Contrast Ultrasound for Abdominal Aortic Aneurysm. Completed, enrolled 66 participants across 1 site.

Detailed Summary

The goal is to non-invasively study the metabolic processes within the aortic wall that are thought to explain progression to clinical manifestations of an aortic aneurysm. Hypothesis is that the non-invasive imaging of Abdominal Aortic Aneurysm (AAA) with contrast ultrasound, coupled with serum biomarker measurements will allow the identification of the vulnerable aortic wall and patients who are at risk of AAA growth or rupture.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAbdominal Aortic Aneurysm
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 27, 2013
Enrollment StartMay 1, 2012
Primary CompletionFeb 1, 2022
TodayJul 2, 2026
Enrollment to primary: 9.8 yearsPosted 12.5 years ago

Interventions

Contrast Ultrasounddrug

Definity® is the contrast agent that will be administered by intravenous injection by a registered nurse during the ultrasound (contrast enhanced ultrasound (CUS). The purpose is to assist in identifying differences in AAA characteristics based on gender and AAA stability and growth.